AEGR up +1.27% percent Today $AEGR High is at 20.9
Post# of 25
Posted On: 11/19/2014 1:29:57 PM
AEGR up +1.27% percent Today $AEGR High is at 20.90 and the Low 20.06 with current volume of 185,843.
Recent News posted below.
Aegerion Pharmaceuticals AEGR other info.
http://investorshangout.com/Aegerion-Pharmace...EGR-53243/
AEGR Aegerion Pharmaceuticals Recent Headline News
Hynes Keller & Hernandez, LLC Announces Investigations of M/A-Com Technology Solutions Holdings, Inc., Stericycle, Inc. and Aegerion Pharmaceuticals, Inc.
PR Newswire - Thu Nov 13, 7:23AM CST
Hynes Keller & Hernandez, LLC is investigating potential claims against M/A-Com Technology Solutions, Stericycle, Inc. and Aegerion Pharmaceuticals, Inc. as detailed below.
MTSI: 23.85 (+0.87), SRCL: 126.76 (-0.43), AEGR: 21.16 (+0.67)
Aegerion Pharmaceuticals awards 35,000 common stock options under NASDAQ Listing Rules
M2 - Thu Nov 13, 6:57AM CST
Biopharmaceutical company Aegerion Pharmaceutical (NasdaqGS:AEGR) on Wednesday announced stock options to purchase an aggregate of 35,000 shares of its common stock to nine new employees entering into employment.
AEGR: 21.16 (+0.67)
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
GlobeNewswire - Wed Nov 12, 3:10PM CST
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced that on November 3, 2014, Aegerion granted stock options to purchase an aggregate of 35,000 shares of common stock to nine new employees under the inducement stock option program described below. Each stock option has an exercise price per share equal to $20.93, the closing price of Aegerion's common stock on the grant date; vests 25% on the first anniversary of the date of grant with the remaining 75% to vest in monthly installments over the three years thereafter; has a ten year term; and is subject to the terms and conditions of Aegerion's Inducement Award Stock Option Plan, and the terms and conditions of a stock option agreement covering the grant.
AEGR: 21.16 (+0.67)
Aegerion to Acquire Myalept, Boost Portfolio - Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 11:52AM CST
Aegerion Pharmaceuticals, Inc. (AEGR) has signed an agreement with AstraZeneca to acquire the latter's Myalept for $325 million.
BIIB: 303.93 (-1.63), AZN: 75.32 (+1.34), LLY: 67.16 (-0.62), AEGR: 21.16 (+0.67), GSK: 46.32 (+0.04)
AstraZeneca (AZN) Misses on Q3 Earnings, Raises Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 2:20PM CST
AstraZeneca (AZN) reported third-quarter 2014 core earnings of $1.05 per ADS that missed the Zacks Consensus Estimate by a penny.
AGN: 213.36 (-0.01), AZN: 75.32 (+1.34), ABBV: 65.49 (-0.56), AEGR: 21.16 (+0.67)
Why Aegerion Pharmaceuticals, Inc. Stock Collapsed in October
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 06, 7:36AM CST
AEGR data by YCharts What: Shares of Aegerion Pharmaceuticals , a biopharmaceutical company focused on developing drugs to treat rare diseases, collapsed in October and lost 40% of their value, based on data from S&P Capital IQ , after...
AMGN: 162.61 (+0.37), AEGR: 21.16 (+0.67)
AstraZeneca divests leptin deficiency med
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 7:31AM CST
AZN: 75.32 (+1.34), AEGR: 21.16 (+0.67)
Aegerion Buys Rare Disease Therapy, Seeking Path Out of Current Troubles
at The Street - Thu Nov 06, 6:55AM CST
Aegerion Pharmaceuticals is spending $325 million, or almost all of its cash, to purchase a recently approved, orphan-disease drug from AstraZeneca.
AZN: 75.32 (+1.34), AEGR: 21.16 (+0.67)
Aegerion Pharmaceuticals Acquires Myalept(TM) From AstraZeneca
GlobeNewswire - Thu Nov 06, 1:11AM CST
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) today announced that it has entered into a definitive agreement with AstraZeneca to acquire Myalept(TM) (metreleptin for injection), an orphan product that is indicated to treat complications of leptin deficiency in patients with generalized lipodystrophy.
AEGR: 21.16 (+0.67)
Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 8:46AM CST
It was another earnings-focused week with several biotech companies yet to report third quarter results.
VRTX: 115.01 (+3.97), GERN: 3.19 (+0.02), AMGN: 162.61 (+0.37), ABBV: 65.49 (-0.56), AEGR: 21.16 (+0.67), SNY: 48.27 (-0.09), REGN: 417.65 (+4.43)
Quarterly Financial Results and Upcoming Conference - Research Reports on Mylan, Aegerion, Bard, Incyte and Boston Scientific
PR Newswire - Wed Nov 05, 7:50AM CST
Today, Analysts Review released its research reports regarding Mylan Inc. (NASDAQ: MYL), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), C.R. Bard, Inc. (NYSE: BCR), Incyte Corporation (NASDAQ: INCY) and Boston Scientific Corporation (NYSE: BSX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7704-100free.
BSX: 13.20 (-0.48), BCR: 166.21 (-1.15), INCY: 71.60 (+1.96), MYL: 55.71 (-0.53), AEGR: 21.16 (+0.67)
Morning Briefing on Biotech Stocks - Arrowhead Research, Array BioPharma, Aegerion Pharma, Hemispherx Biopharma, and Aeterna Zentaris
PR Newswire - Wed Nov 05, 7:30AM CST
Investor-Edge has initiated coverage on the following equities: Arrowhead Research Corporation (NASDAQ: ARWR), Array BioPharma Inc. (NASDAQ: ARRY), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), Hemispherx Biopharma Inc. (NYSE MKT: HEB), and Aeterna Zentaris Inc. (NASDAQ: AEZS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, November 4, 2014, the NASDAQ Composite ended at 4,623.64, down 0.33%, the Dow Jones Industrial Average advanced 0.10%, to finish the day at 17,383.84, and the S&P 500 closed at 2,012.10, down 0.28%. During the session, five out of ten sectors ended in positive. The S&P 500 Health Care Sector Index ended the day at 779.72, up 0.09%, with the index also advancing 10.19% in the previous three months. Register for your complimentary reports on these five stocks at:
ARWR: 5.86 (-0.09), HEB: 0.27 (unch), AEZS: 0.53 (-0.02), AEGR: 21.16 (+0.67), ARRY: 3.59 (-0.08)
Aegerion Pharmaceuticals (AEGR) Is Today's Dead Cat Bounce Stock
at The Street - Mon Nov 03, 11:46AM CST
Trade-Ideas LLC identified Aegerion Pharmaceuticals (AEGR) as a "dead cat bounce" (down big yesterday but up big today) candidate
AEGR: 21.16 (+0.67)
Nasdaq stocks posting largest volume increases
AP - Fri Oct 31, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
ONCY: 0.67 (-0.03), IMRS: 0.22 (-0.01), IM.TO: 0.25 (-0.01), FCCO: 10.74 (+0.03), RDI: 11.71 (-0.06), CDTI: 2.31 (-0.04), ONC.TO: 0.77 (-0.02), DAIO: 3.51 (+0.09), AEGR: 21.16 (+0.67), RDIB: 11.84 (-0.16)
Nasdaq stocks posting largest percentage decreases
AP - Fri Oct 31, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
ASMI: 42.16 (+0.14), TRMB: 28.05 (-0.55), STAA: 8.70 (unch), SCYX: 9.58 (+0.08), EPAY: 24.95 (-0.53), AEGR: 21.16 (+0.67)
AEGERION ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Aegerion Pharmaceuticals, Inc.
Business Wire - Fri Oct 31, 3:43PM CDT
Shareholder rights law firm Johnson & Weaver, LLP has commenced an investigation into whether certain officers and directors of Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR) violated state or federal laws.
AEGR: 21.16 (+0.67)
LinkedIn and GoPro are big market movers
AP - Fri Oct 31, 3:32PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
SBUX: 78.02 (+0.45), LNKD: 220.84 (-0.23), TPX: 55.14 (+0.84), AEGR: 21.16 (+0.67), FSL: 20.13 (-0.39), GRPN: 7.39 (+0.02)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 11:47AM CDT
MEP: 15.66 (-0.17), SREV: 4.20 (-0.05), SGMS: 12.67 (+0.04), CDTI: 2.31 (-0.04), NKA: 5.71 (+0.54), WETF: 15.27 (-0.14), EPAY: 24.95 (-0.53), AEGR: 21.16 (+0.67), YOD: 2.05 (-0.07), RM: 12.42 (-0.27), GCAP: 9.02 (-0.09), MGI: 8.55 (-0.01), KGC: 2.93 (-0.03), STAA: 8.70 (unch), ADNC: 3.60 (unch), GRPN: 7.39 (+0.02), MELI: 136.38 (+0.88), IMPV: 41.95 (-0.58), OPLK: 24.17 (+2.92), CODE: 21.16 (-0.13)
Why Shares of Aegerion Phaemaceuticals, Inc. Were Obliterated Today
Alex Planes, The Motley Fool - Motley Fool - Fri Oct 31, 11:34AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Aegerion Pharmaceuticals lost nearly 40%...
AEGR: 21.16 (+0.67)
Recent News posted below.
Aegerion Pharmaceuticals AEGR other info.
http://investorshangout.com/Aegerion-Pharmace...EGR-53243/
AEGR Aegerion Pharmaceuticals Recent Headline News
Hynes Keller & Hernandez, LLC Announces Investigations of M/A-Com Technology Solutions Holdings, Inc., Stericycle, Inc. and Aegerion Pharmaceuticals, Inc.
PR Newswire - Thu Nov 13, 7:23AM CST
Hynes Keller & Hernandez, LLC is investigating potential claims against M/A-Com Technology Solutions, Stericycle, Inc. and Aegerion Pharmaceuticals, Inc. as detailed below.
MTSI: 23.85 (+0.87), SRCL: 126.76 (-0.43), AEGR: 21.16 (+0.67)
Aegerion Pharmaceuticals awards 35,000 common stock options under NASDAQ Listing Rules
M2 - Thu Nov 13, 6:57AM CST
Biopharmaceutical company Aegerion Pharmaceutical (NasdaqGS:AEGR) on Wednesday announced stock options to purchase an aggregate of 35,000 shares of its common stock to nine new employees entering into employment.
AEGR: 21.16 (+0.67)
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
GlobeNewswire - Wed Nov 12, 3:10PM CST
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced that on November 3, 2014, Aegerion granted stock options to purchase an aggregate of 35,000 shares of common stock to nine new employees under the inducement stock option program described below. Each stock option has an exercise price per share equal to $20.93, the closing price of Aegerion's common stock on the grant date; vests 25% on the first anniversary of the date of grant with the remaining 75% to vest in monthly installments over the three years thereafter; has a ten year term; and is subject to the terms and conditions of Aegerion's Inducement Award Stock Option Plan, and the terms and conditions of a stock option agreement covering the grant.
AEGR: 21.16 (+0.67)
Aegerion to Acquire Myalept, Boost Portfolio - Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 11:52AM CST
Aegerion Pharmaceuticals, Inc. (AEGR) has signed an agreement with AstraZeneca to acquire the latter's Myalept for $325 million.
BIIB: 303.93 (-1.63), AZN: 75.32 (+1.34), LLY: 67.16 (-0.62), AEGR: 21.16 (+0.67), GSK: 46.32 (+0.04)
AstraZeneca (AZN) Misses on Q3 Earnings, Raises Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 2:20PM CST
AstraZeneca (AZN) reported third-quarter 2014 core earnings of $1.05 per ADS that missed the Zacks Consensus Estimate by a penny.
AGN: 213.36 (-0.01), AZN: 75.32 (+1.34), ABBV: 65.49 (-0.56), AEGR: 21.16 (+0.67)
Why Aegerion Pharmaceuticals, Inc. Stock Collapsed in October
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 06, 7:36AM CST
AEGR data by YCharts What: Shares of Aegerion Pharmaceuticals , a biopharmaceutical company focused on developing drugs to treat rare diseases, collapsed in October and lost 40% of their value, based on data from S&P Capital IQ , after...
AMGN: 162.61 (+0.37), AEGR: 21.16 (+0.67)
AstraZeneca divests leptin deficiency med
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 7:31AM CST
AZN: 75.32 (+1.34), AEGR: 21.16 (+0.67)
Aegerion Buys Rare Disease Therapy, Seeking Path Out of Current Troubles
at The Street - Thu Nov 06, 6:55AM CST
Aegerion Pharmaceuticals is spending $325 million, or almost all of its cash, to purchase a recently approved, orphan-disease drug from AstraZeneca.
AZN: 75.32 (+1.34), AEGR: 21.16 (+0.67)
Aegerion Pharmaceuticals Acquires Myalept(TM) From AstraZeneca
GlobeNewswire - Thu Nov 06, 1:11AM CST
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) today announced that it has entered into a definitive agreement with AstraZeneca to acquire Myalept(TM) (metreleptin for injection), an orphan product that is indicated to treat complications of leptin deficiency in patients with generalized lipodystrophy.
AEGR: 21.16 (+0.67)
Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 8:46AM CST
It was another earnings-focused week with several biotech companies yet to report third quarter results.
VRTX: 115.01 (+3.97), GERN: 3.19 (+0.02), AMGN: 162.61 (+0.37), ABBV: 65.49 (-0.56), AEGR: 21.16 (+0.67), SNY: 48.27 (-0.09), REGN: 417.65 (+4.43)
Quarterly Financial Results and Upcoming Conference - Research Reports on Mylan, Aegerion, Bard, Incyte and Boston Scientific
PR Newswire - Wed Nov 05, 7:50AM CST
Today, Analysts Review released its research reports regarding Mylan Inc. (NASDAQ: MYL), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), C.R. Bard, Inc. (NYSE: BCR), Incyte Corporation (NASDAQ: INCY) and Boston Scientific Corporation (NYSE: BSX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7704-100free.
BSX: 13.20 (-0.48), BCR: 166.21 (-1.15), INCY: 71.60 (+1.96), MYL: 55.71 (-0.53), AEGR: 21.16 (+0.67)
Morning Briefing on Biotech Stocks - Arrowhead Research, Array BioPharma, Aegerion Pharma, Hemispherx Biopharma, and Aeterna Zentaris
PR Newswire - Wed Nov 05, 7:30AM CST
Investor-Edge has initiated coverage on the following equities: Arrowhead Research Corporation (NASDAQ: ARWR), Array BioPharma Inc. (NASDAQ: ARRY), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), Hemispherx Biopharma Inc. (NYSE MKT: HEB), and Aeterna Zentaris Inc. (NASDAQ: AEZS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, November 4, 2014, the NASDAQ Composite ended at 4,623.64, down 0.33%, the Dow Jones Industrial Average advanced 0.10%, to finish the day at 17,383.84, and the S&P 500 closed at 2,012.10, down 0.28%. During the session, five out of ten sectors ended in positive. The S&P 500 Health Care Sector Index ended the day at 779.72, up 0.09%, with the index also advancing 10.19% in the previous three months. Register for your complimentary reports on these five stocks at:
ARWR: 5.86 (-0.09), HEB: 0.27 (unch), AEZS: 0.53 (-0.02), AEGR: 21.16 (+0.67), ARRY: 3.59 (-0.08)
Aegerion Pharmaceuticals (AEGR) Is Today's Dead Cat Bounce Stock
at The Street - Mon Nov 03, 11:46AM CST
Trade-Ideas LLC identified Aegerion Pharmaceuticals (AEGR) as a "dead cat bounce" (down big yesterday but up big today) candidate
AEGR: 21.16 (+0.67)
Nasdaq stocks posting largest volume increases
AP - Fri Oct 31, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
ONCY: 0.67 (-0.03), IMRS: 0.22 (-0.01), IM.TO: 0.25 (-0.01), FCCO: 10.74 (+0.03), RDI: 11.71 (-0.06), CDTI: 2.31 (-0.04), ONC.TO: 0.77 (-0.02), DAIO: 3.51 (+0.09), AEGR: 21.16 (+0.67), RDIB: 11.84 (-0.16)
Nasdaq stocks posting largest percentage decreases
AP - Fri Oct 31, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
ASMI: 42.16 (+0.14), TRMB: 28.05 (-0.55), STAA: 8.70 (unch), SCYX: 9.58 (+0.08), EPAY: 24.95 (-0.53), AEGR: 21.16 (+0.67)
AEGERION ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Aegerion Pharmaceuticals, Inc.
Business Wire - Fri Oct 31, 3:43PM CDT
Shareholder rights law firm Johnson & Weaver, LLP has commenced an investigation into whether certain officers and directors of Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR) violated state or federal laws.
AEGR: 21.16 (+0.67)
LinkedIn and GoPro are big market movers
AP - Fri Oct 31, 3:32PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
SBUX: 78.02 (+0.45), LNKD: 220.84 (-0.23), TPX: 55.14 (+0.84), AEGR: 21.16 (+0.67), FSL: 20.13 (-0.39), GRPN: 7.39 (+0.02)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 11:47AM CDT
MEP: 15.66 (-0.17), SREV: 4.20 (-0.05), SGMS: 12.67 (+0.04), CDTI: 2.31 (-0.04), NKA: 5.71 (+0.54), WETF: 15.27 (-0.14), EPAY: 24.95 (-0.53), AEGR: 21.16 (+0.67), YOD: 2.05 (-0.07), RM: 12.42 (-0.27), GCAP: 9.02 (-0.09), MGI: 8.55 (-0.01), KGC: 2.93 (-0.03), STAA: 8.70 (unch), ADNC: 3.60 (unch), GRPN: 7.39 (+0.02), MELI: 136.38 (+0.88), IMPV: 41.95 (-0.58), OPLK: 24.17 (+2.92), CODE: 21.16 (-0.13)
Why Shares of Aegerion Phaemaceuticals, Inc. Were Obliterated Today
Alex Planes, The Motley Fool - Motley Fool - Fri Oct 31, 11:34AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Aegerion Pharmaceuticals lost nearly 40%...
AEGR: 21.16 (+0.67)
(0)
(0)